Hansa Biopharma AB - Company Profile
Powered by 
All the sales intelligence you need on Hansa Biopharma AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hansa Biopharma AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hansa Biopharma AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for the treatment of rare and acute medical conditions characterized by pathogenic antibodies. Strong market position in Europe, innovative R&D and pipeline development, and strategic collaborations and partnerships are its strengths, while operating loss carry forward could be an area for concern. The company could benefit from orphan drug designation for IdeS, market potential of Limb-Girdle Muscular Dystrophy, and growing market for Duchenne Muscular Dystrophy. Nevertheless, its performance can be affected by uncertain R&D outcomes, government regulations and competitive environment.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer